COCH press release
RTPR•17/11/2026•09:15 ET
1
Key Highlights
- ➤99 granted patents globally after two additional U.S. and Hong Kong grants
- ➤U.S. Patent No. 12,773,553 covers cochlear implant electrode impedance diagnostics
- ➤Hong Kong Patent No. HK40105814 covers integrated signal analysis functionality
- ➤32 patent applications remain pending, including 24 foreign and eight U.S.
- ➤Acclaim cochlear implant remains under investigation in a U.S.-based pivotal clinical trial
New Patents Cover Cochlear Implant Electrode Impedance Diagnostics and Integrated Signal Analysis Functionality
White Bear Lake, Minnesota--(Newsfile Corp. - November 17, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced it has been granted two additional patents in the United States and Hong Kong, bringing its intellectual property portfolio to 99 patents. In addition, the Company has 24 pending foreign applications and eight pending U.S. applications, further expanding its intellectual property portfolio.
Get started
Create a free account to read the full story.
